Indeed, several early clinical trials of anti-LAG-3 monoclonal antibodies or anti-Tim-3 monoclonal antibodies combined with PD-1 inhibitors are being conducted in several tumor types, including RCC (Table 1). Here, LAG3 is linked to neoplasm.